These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10867451)

  • 1. What's new with tumor markers for colorectal cancer?
    Pokorny RM; Hunt L; Galandiuk S
    Dig Surg; 2000; 17(3):209-15. PubMed ID: 10867451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
    Knychalski B; Lukieńczuk T
    Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers and colorectal cancer: utility in management.
    Crawford NP; Colliver DW; Galandiuk S
    J Surg Oncol; 2003 Dec; 84(4):239-48. PubMed ID: 14756436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma sialic acid as a marker of the effect of the treatment on metastatic colorectal cancer.
    Painbeni T; Gamelin E; Cailleux A; Le Bouil A; Boisdron-Celle M; Daver A; Larra F; Allain P
    Eur J Cancer; 1997 Nov; 33(13):2216-20. PubMed ID: 9470809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
    Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
    Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor markers for colorectal cancer].
    Yamamoto H; Miyake Y; Noura S; Ogawa M; Yasui M; Ikenaga M; Sekimoto M; Monden M
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1299-305. PubMed ID: 11579645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA 72-4 serum marker--a new tool in the management of carcinoma patients.
    Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Cavaliere F; Casaldi V; Wappner G; Abbolito MR; Greiner JW
    Cancer Invest; 1995; 13(2):227-38. PubMed ID: 7874576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Standards, options and recommendations for tumor markers in colorectal cancer].
    Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
    Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics.
    Mourtzikou A; Stamouli M; Kroupis C; Christodoulou S; Skondra M; Kastania A; Pectasides D; Athanasas G; Dimas C
    Clin Lab; 2012; 58(5-6):441-8. PubMed ID: 22783573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
    Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
    Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
    Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers.
    Emara M; Cheung PY; Grabowski K; Sawicki G; Wozniak M
    Clin Chem Lab Med; 2009; 47(8):993-1000. PubMed ID: 19569980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody 4D3 detects small intestinal mucin antigen (SIMA)--glycoprotein in the serum of patients with colorectal cancer.
    Pinczower GD; Gianello RD; Williams RP; Preston BN; Preston H; Linnane AW
    Int J Cancer; 1993 May; 54(3):391-6. PubMed ID: 8509213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of serum CA 19-9 and CEA levels in a population at high risk for colorectal cancer.
    Goldberg EM; Simunovic LM; Drake SL; Mueller WF; Verrill HL
    Hybridoma; 1989 Oct; 8(5):569-75. PubMed ID: 2807313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
    Grotowski M
    Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.